Prime Medicine
15 articles with Prime Medicine
-
Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities
1/9/2023
Prime Medicine, Inc. provided an update on recent advancements of its Prime Editing technology and progress across its initial pipeline of eighteen programs, and outlined its strategic priorities and expected milestones for 2023.
-
Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Prime Medicine, Inc. announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15 a.m. PT in San Francisco, CA.
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
-
Prime Medicine Announces Closing of Upsized Initial Public Offering
10/24/2022
Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the closing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share.
-
Prime Medicine Announces Pricing of Upsized Initial Public Offering
10/19/2022
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share.
-
Funding initiatives this week saw money flow into cancer, rare liver diseases, respiratory depression, chemotherapy-related toxicities and a cutting-edge machine learning platform.
-
Prime Medicine Appoints Three New Directors to its Board of Directors
8/11/2022
Prime Medicine, Inc. today announced that Wendy Chung, M.D., Ph.D., Kaye Foster and Michael A. Kelly have been appointed to the company’s board of directors.
-
Prime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio
7/28/2022
Prime Medicine, Inc. today announced the expansion of the company’s leadership team with the appointments of the following executives.
-
Myeloid Therapeutics has signed an exclusive collaboration deal with Prime Medicine to leverage both companies' technologies and discover cancer and autoimmune diseases treatments.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
-
Prime Medicine Announces Addition of Capabilities to Prime Editing Platform
10/19/2021
Prime Medicine, Inc., a company founded to deliver on the promise of Prime Editing, announced the addition of capabilities to its platform based on recent scientific research.
-
Prime Medicine Appoints Ann L. Lee as Chief Technical Officer
10/13/2021
Prime Medicine™, a company delivering on the promise of Prime Editing to provide lifelong cures to patients, announced the appointment of Ann L. Lee, PhD, as Chief Technical Officer.
-
The company's technology aims to precisely search out genetic mutations at their precise genome location, limiting concerns about toxicities or unwanted cellular changes.